<?xml version='1.0' encoding='utf-8'?>
<document id="31660706"><sentence text="The effect of esomeprazole vs famotidine on aspirin/clopidogrel dual therapy after percutaneous coronary intervention."><entity charOffset="14-26" id="DDI-PubMed.31660706.s1.e0" text="esomeprazole" /><entity charOffset="30-40" id="DDI-PubMed.31660706.s1.e1" text="famotidine" /><entity charOffset="44-51" id="DDI-PubMed.31660706.s1.e2" text="aspirin" /><entity charOffset="52-63" id="DDI-PubMed.31660706.s1.e3" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e0" e2="DDI-PubMed.31660706.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e0" e2="DDI-PubMed.31660706.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e0" e2="DDI-PubMed.31660706.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e0" e2="DDI-PubMed.31660706.s1.e3" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e1" e2="DDI-PubMed.31660706.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e1" e2="DDI-PubMed.31660706.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e1" e2="DDI-PubMed.31660706.s1.e3" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e2" e2="DDI-PubMed.31660706.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s1.e2" e2="DDI-PubMed.31660706.s1.e3" /></sentence><sentence text="Regarding drug interactions between proton pump inhibitors (PPIs) and dual antiplatelet therapy (DAPT), controversies have arisen over the possibility that PPIs may interfere with the antiplatelet effect of DAPT" /><sentence text=" However, whether this interaction is drug-specific or a class effect needs to be determined" /><sentence text=" It is not clear whether famotidine, an H2-receptor antagonist (H2RA), interacts with DAPT"><entity charOffset="25-35" id="DDI-PubMed.31660706.s4.e0" text="famotidine" /><entity charOffset="86-90" id="DDI-PubMed.31660706.s4.e1" text="DAPT" /><pair ddi="false" e1="DDI-PubMed.31660706.s4.e0" e2="DDI-PubMed.31660706.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31660706.s4.e0" e2="DDI-PubMed.31660706.s4.e1" /></sentence><sentence text="" /><sentence text="The aim of this study was to assess the impact of esomeprazole and famotidine on the efficacy of DAPT"><entity charOffset="50-62" id="DDI-PubMed.31660706.s6.e0" text="esomeprazole" /><entity charOffset="67-77" id="DDI-PubMed.31660706.s6.e1" text="famotidine" /><entity charOffset="97-106" id="DDI-PubMed.31660706.s6.e2" text="DAPT" /><pair ddi="false" e1="DDI-PubMed.31660706.s6.e0" e2="DDI-PubMed.31660706.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31660706.s6.e0" e2="DDI-PubMed.31660706.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s6.e0" e2="DDI-PubMed.31660706.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s6.e1" e2="DDI-PubMed.31660706.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s6.e1" e2="DDI-PubMed.31660706.s6.e2" /></sentence><sentence text="" /><sentence text="The study involved 160 patients undergoing elective percutaneous coronary interventions and treated with DAPT and concomitant use of esomeprazole (40 mg/d) or famotidine (40 mg/d)"><entity charOffset="133-145" id="DDI-PubMed.31660706.s8.e0" text="esomeprazole" /><entity charOffset="159-169" id="DDI-PubMed.31660706.s8.e1" text="famotidine" /><entity charOffset="105-114" id="DDI-PubMed.31660706.s8.e2" text="DAPT" /><pair ddi="false" e1="DDI-PubMed.31660706.s8.e2" e2="DDI-PubMed.31660706.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s8.e2" e2="DDI-PubMed.31660706.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31660706.s8.e2" e2="DDI-PubMed.31660706.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s8.e0" e2="DDI-PubMed.31660706.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31660706.s8.e0" e2="DDI-PubMed.31660706.s8.e1" /></sentence><sentence text=" Platelet reactivity was measured with adenosine diphosphate (ADP)-induced light transmittance aggregometry (LTA) and vasodilator-stimulated phosphoprotein phosphorylation-platelet reactivity index (VASP-PRI) at baseline, 14 and 30 days after applying randomized acid-suppressing agents"><entity charOffset="39-60" id="DDI-PubMed.31660706.s9.e0" text="adenosine diphosphate" /></sentence><sentence text="" /><sentence text="No significance differences were observed in treatment-by-period interactions with LTA values (p = 0" /><sentence text="298) and VASP-PRI values (p = 0" /><sentence text="867), which suggested no carryover effect in either regimen over the 30-day treatment period" /><sentence text=" Intergroup comparisons were done between the 2 groups at 3 times, and similar findings were observed at each time (all p &gt; 0" /><sentence text="05)" /><sentence text=" As for intragroup measurements among the separate times, significantly lower LTA and VASP-PRI values existed on day 14 for both agents (both p &lt; 0" /><sentence text="05)" /><sentence text="" /><sentence text="The antiplatelet effect of DAPT was not affected by concomitant use of esomeprazole or famotidine"><entity charOffset="27-31" id="DDI-PubMed.31660706.s19.e0" text="DAPT" /><entity charOffset="71-83" id="DDI-PubMed.31660706.s19.e1" text="esomeprazole" /><entity charOffset="87-97" id="DDI-PubMed.31660706.s19.e2" text="famotidine" /><pair ddi="false" e1="DDI-PubMed.31660706.s19.e0" e2="DDI-PubMed.31660706.s19.e0" /><pair ddi="false" e1="DDI-PubMed.31660706.s19.e0" e2="DDI-PubMed.31660706.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s19.e0" e2="DDI-PubMed.31660706.s19.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s19.e1" e2="DDI-PubMed.31660706.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s19.e1" e2="DDI-PubMed.31660706.s19.e2" /></sentence><sentence text=" These 2 agents were much less likely than CYP2C19 polymorphisms to influence aspirin/clopidogrel therapy, supporting the assertion that the pharmacodynamic interaction between aspirin/clopidogrel and acid-suppressing agents is a drug-specific rather than a class effect"><entity charOffset="78-85" id="DDI-PubMed.31660706.s20.e0" text="aspirin" /><entity charOffset="86-97" id="DDI-PubMed.31660706.s20.e1" text="clopidogrel" /><entity charOffset="177-184" id="DDI-PubMed.31660706.s20.e2" text="aspirin" /><entity charOffset="185-196" id="DDI-PubMed.31660706.s20.e3" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e0" e2="DDI-PubMed.31660706.s20.e0" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e0" e2="DDI-PubMed.31660706.s20.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e0" e2="DDI-PubMed.31660706.s20.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e0" e2="DDI-PubMed.31660706.s20.e3" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e1" e2="DDI-PubMed.31660706.s20.e1" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e1" e2="DDI-PubMed.31660706.s20.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e1" e2="DDI-PubMed.31660706.s20.e3" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e2" e2="DDI-PubMed.31660706.s20.e2" /><pair ddi="false" e1="DDI-PubMed.31660706.s20.e2" e2="DDI-PubMed.31660706.s20.e3" /></sentence><sentence text="" /></document>